Login to Your Account



FDA Insists on Priority Review For VMA Drug Ocriplasmin

By Cormac Sheridan
Staff Writer

Wednesday, February 8, 2012

Even though ThromboGenics NV decided not to seek a priority review of its BLA for its symptomatic vitreomacular adhesion (VMA) drug ocriplasmin, the FDA decided to bestow one on the company anyway. The Leuven, Belgium-based firm now plans to withdraw its original BLA and to re-submit the file in April. The fast-track procedure should lead to a decision within six months.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription